Infiltrative tumor-associated macrophage (TAM) inhibitors, along with anti-PD-L1 therapy, can eliminate PD-L1+ TAM infiltration and neutralize CD8+ T-cell suppression in HCC. The gene discussed is CD8A; the disease is hepatocellular carcinoma.